Literature DB >> 29243296

Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas.

Mark Kriegsmann1, Alexander Harms1,2, Rémi Longuespée1, Thomas Muley2,3, Hauke Winter2,4, Katharina Kriegsmann5, Daniel Kazdal1,2, Benjamin Goeppert1, Anita Pathil6, Arne Warth1,2.   

Abstract

AIMS: Pulmonary (ADC) and colorectal (CRC) adenocarcinomas are frequent entities in pathological routine diagnostics. Whereas the differential diagnosis is usually straightforward based on histomorphology, it can be challenging in small biopsies. In general, CDX-2, CK20, Napsin-A and TTF-1 are recommended immunohistological markers in this scenario. Hepatocyte nuclear factor 4 alpha (HNF4-α) and special AT-rich sequence-binding protein 2 (SATB2) were described recently as promising additional markers, but comprehensive large-scale data are lacking so far. Therefore, we analysed the expression of these six markers in 1021 non-small-cell lung cancers (NSCLC), including 472 ADC as well as in 80 pulmonary metastases of CRC. METHODS AND
RESULTS: Tissue microarrays of NSCLC and pulmonary metastases of CRC were stained for CDX-2, CK20, HNF4-α, Napsin-A, SATB2 and TTF-1 and staining results were correlated with clinicopathological variables. ADC exhibited expression of CDX-2, CK20, HNF4-α, Napsin-A, SATB2 and TTF-1 in nine (2%), 21 (4%), 17 (4%), 345 (73%), 35 (7%) and 408 (86%) samples, while 80 CRC were positive in 79 (99%), 74 (93%), 77 (96%), no (0%), 78 (98%) and five (6%) cases, respectively.
CONCLUSIONS: In addition to conventional immunomarkers, HNF4-α and particularly SATB2 may be helpful in the differential diagnosis of pulmonary ADC and metastases of CRC.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990NSCLCzzm321990; HNF4-a; SATB2; colorectal; immunohistology

Mesh:

Substances:

Year:  2018        PMID: 29243296     DOI: 10.1111/his.13455

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases.

Authors:  Matthew M Yeh; Dustin E Bosch; Sayed S Daoud
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

2.  HNF4A Regulates the Proliferation and Tumor Formation of Cervical Cancer Cells through the Wnt/β-Catenin Pathway.

Authors:  Hong-Mei Ma; Qian Zhang; Xue-Mei Yang; Yan Hu; Juan Zhang; Lin Chen; Bin Zhao; Wen-Ting Yang; Rui Xu
Journal:  Oxid Med Cell Longev       Date:  2022-01-28       Impact factor: 6.543

3.  Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms.

Authors:  Silvia Uccella; Carla Facco; Anna Maria Chiaravalli; Fabiana Pettenon; Stefano La Rosa; Mario Turri-Zanoni; Paolo Castelnuovo; Michele Cerati; Fausto Sessa
Journal:  Endocr Pathol       Date:  2022-05-06       Impact factor: 4.056

4.  MicroRNA-766-3p-mediated downregulation of HNF4G inhibits proliferation in colorectal cancer cells through the PI3K/AKT pathway.

Authors:  Xin-Xin He; Shan-Shan Luo; Hai-Quan Qin; Xian-Wei Mo
Journal:  Cancer Gene Ther       Date:  2021-06-22       Impact factor: 5.854

5.  Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer.

Authors:  Mark Kriegsmann; Katharina Kriegsmann; Alexander Harms; Rémi Longuespée; Christiane Zgorzelski; Jonas Leichsenring; Thomas Muley; Hauke Winter; Daniel Kazdal; Benjamin Goeppert; Arne Warth
Journal:  Diagn Pathol       Date:  2018-09-11       Impact factor: 2.644

6.  Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.

Authors:  Maxime Schmitt; Miguel Silva; Björn Konukiewitz; Corinna Lang; Katja Steiger; Kathrin Halfter; Jutta Engel; Paul Jank; Nicole Pfarr; Dirk Wilhelm; Sebastian Foersch; Carsten Denkert; Markus Tschurtschenthaler; Wilko Weichert; Moritz Jesinghaus
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.